Metabolic Solutions Inc

Metabolic Solutions Inc

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $85M

Overview

Metabolic Solutions Inc. is a US-based, privately-held service provider specializing in stable isotope tracer analysis for metabolic research in drug development. Founded in 2006, the company offers an end-to-end solution from protocol design to submission-ready reports, leveraging over 35 years of collective expertise in the field. It serves as a critical partner for pharma and biotech companies, providing high-confidence, GLP-compliant data to validate mechanisms of action and make faster go/no-go decisions. The company operates from facilities in Nashua, NH, and Kalamazoo, MI, and is positioned as a niche, high-expertise CRO within the broader metabolic research landscape.

Obesity & Metabolic HealthFibrosisOncologyRare Diseases & Gene TherapyGastrointestinal & Liver Health

Technology Platform

Specialized stable isotope tracer analysis platform utilizing mass spectrometry to measure in vivo metabolic fluxes (e.g., glucose kinetics, protein turnover, collagen synthesis, cell proliferation) and non-invasive breath tests for organ function.

Funding History

2
Total raised:$85M
Series B$60M
Series A$25M

Opportunities

Strong demand is driven by the growing pipeline of metabolic, fibrotic, and rare disease drugs requiring deep mechanism-of-action data.
The expansion of gene therapy and the industry's focus on translational biomarkers present significant growth avenues.
The company can leverage its unique data to potentially develop novel diagnostic or prognostic biomarker panels.

Risk Factors

Key risks include over-reliance on a niche technology, potential client concentration, and dependence on a small group of highly specialized scientific personnel.
Competition from larger CROs developing internal capabilities and technological obsolescence are additional threats.

Competitive Landscape

MSI competes as a niche specialist against broad-service CROs and central labs that may offer some isotopic analysis but lack its depth and end-to-end service model. Its primary competitive advantage is over 35 years of focused expertise, regulatory-ready assays, and a partnership-oriented approach, differentiating it from generic vendors.